About Us
CRISPRomics®
+
CRISPRomics®
Publications
Pipeline
+
Pipeline®
Expanded Access Policy
News
People
+
Leadership Team
Board of Directors
Careers
Contact
Follow us on Twitter
Find us on LinkedIn
EROTC Poster Presentation
October 24, 2020
“Development of KSQ-4279 as a First-in-Class USP1 Inhibitor for the Treatment of BRCA-Deficient Cancers”
© 2023 KSQ Therapeutics, Inc. All rights reserved.